Search results
Results from the WOW.Com Content Network
Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies .
William Bradley Coley (January 12, 1862 – April 16, 1936) was an American bone surgeon and cancer researcher best known for his early contributions to the study of cancer immunotherapy, specifically causing infection as a way to fight cancer, a practice used as far back as 1550 BC. [1]
Kiril Bratanov (1911-1986), pioneer in the area of immunology of reproduction; William Coley (1862-1936), pioneer of cancer immunotherapy; Albert Coons (1912-1978), developed immunofluorescent techniques for labelling antibodies; Max D. Cooper (1933-), identification of T and B cells; Yehuda Danon (1940-) Deborah Doniach (1912-2004), organ ...
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology ( immuno-oncology ) and a growing subspecialty of oncology .
The Breakthrough is written for the lay reader and includes sections on immunology that have been written for a general audience. It examines the development of cancer immunotherapy, starting with William Coley's work with toxins in the 1890s, moving on to the long hiatus of immunotherapy, and concluding with victory for the believers in the form of regulatory approval of CTLA-4, PD-1, and PD ...
Jimmy Carter is celebrating his historic 100th birthday.. The former president — who holds the record for the nation's longest-lived president — has spent 19 months in hospice care but has ...
Image credits: Detroit Photograph Company "There was a two-color process invented around 1913 by Kodak that used two glass plates in contact with each other, one being red-orange and the other ...
In September 2014, a new cancer immunotherapy for melanoma patients called Keytruda became the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States. Jeffrey Weber, director of the Donald A. Adam Comprehensive Melanoma Research Center of Excellence at Moffitt, was one of the lead investigators of the clinical trial ...